Gossamer Bio advances its inhaled kinase inhibitor seralutinib through pivotal Phase 3 data for pulmonary hypertension, showing clinically meaningful albeit narrowly missed statistical endpoints. The company’s strategic alliance with Chiesi mitigates development costs while sharing commercialization profits in the U.S. However, escalating R&D expenses deepen operating deficits, challenging cash reserves despite sizeable past equity raises and convertible note issuance. Near-term outcomes hinge on FDA interactions and seralutinib’s regulatory approval prospects, balanced against substantial capital requirements and intrinsic industry risks.